As mentioned by Lingvay et al., semaglutide has shown promise as a treatment option for non-diabetics with established atherosclerotic disease by reducing their risk of MACE by 20% despite having varying HBA1c baselines [47]
The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
State Medicaid programs, Medicare Advantage payers, commercial payers, the Veterans Health Administration, and the Indian Health Service are all implementing and evaluating various FIM programs
It is a dissolving-type microneedle technology that offers skin-based, precise drug delivery
However, they differ in a key way: tirzepatide is a dual agonist (GLP-1 and GIP), while retatrutide is a triple agonist (GLP-1, GIP, and GCG)
Alibilli, A.S., Jain, V., Mane, H., Yue, X., Ratzki-Leewing, A., Merchant, J.S., Criss, S., Nguyen, Q.C., McCoy, R.G., Nguyen, T.T
